Statins Market Segmented By Astrovastatins, Fluvastatins, Lovastatins, Pravastatins, Simvastatins Drug Class for Cardiovascular Disorders, Obesity, Inflammatory Disorders Treatment
Industry: Healthcare
Published Date: September-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP3038
The global statins market size reached US$ 15 Bn in 2021 and is expected to touch US$ 22 Bn by 2032, advancing at 3.5% CAGR from 2022 to 2032 (forecast period).
The United States is expected to hold the largest share of the global statins market in North America.
Report Attribute | Details |
---|---|
Statins Market Size (2021) |
US$ 15 Bn |
Projected Market Value (2032) |
US$ 22 Bn |
Global Market Growth Rate (2022-2032) |
3.5% CAGR |
U.S. Market Value (2021) |
US$ 45 Mn |
“Rising Cases of High Cholesterol & Obesity across the World”
Global demand for statins is anticipated to grow as the incidence of cholesterol rises due to changing lifestyles. Increasing sedentary lifestyles in developed regions is a major factor that is projected to boost the global statins market.
Since high cholesterol is difficult to control only through exercise and diet, statins are highly suggested to address the issue. Furthermore, the demand for statins is expanding as a result of cholesterol awareness initiatives and technologically upgraded medical facilities. The increasing pace of urbanization is causing more cholesterol-associated diseases and assuring that statins are in high demand.
Moreover, the growing use of combination therapies that combine statins with additional cholesterol-lowering medications, such as ezetimibe, is expected to propel the global market.
In addition, escalating number of obese and overweight people is anticipated to spur the growth of the global statins market. Germany, India, China, the United Kingdom, and the United States have the world's largest obese populations.
Obesity causes a variety of health issues, such as diabetes, high cholesterol levels, and respiratory issues, as well as other acute and chronic disorders. As a result, the rising prevalence of obesity around the world is expected to drive the sales of statins over the coming years.
“Increasing Investments in R&D to Provide Market Growth Opportunities”
Increasing investments in research and development to improve technologies and medical instruments, both, in developing and developed nations, are likely to provide revenue-generation opportunities for manufacturers of statins during the forecast period.
Moreover, growing research and development efforts to deliver effective treatments are projected to boost the global market stance going ahead.
“Strong Focus on Improving Healthcare Facilities”
Increased emphasis on enhancing the state of medical facilities and overall healthcare systems is a significant factor estimated to bolster the global statins market.
Moreover, a growing number of strategic collaborations and partnerships between private and public entities to fund and deploy new and improved technologies is expected to provide massive growth prospects to market players.
“North America to Maintain Dominance”
North America dominated the global statins market and is expected to maintain its dominance throughout the projection period. The presence of a large number of people suffering from cardiovascular diseases is projected to boost the statins market in North America.
Moreover, a rise in the incidence of diabetes, obesity, and cardiovascular disease among the elderly is anticipated to fuel the demand for effective high cholesterol treatment.
The United States is likely to be the largest revenue generator in the statins market in North America.
Leading players operating in the regional market are expected to experience substantial growth during the forecast period. Moreover, statin usage is high among the senior population, which is projected to drive regional market growth for years to come.
Statins are a special class of drugs that helps in lowering blood cholesterol level in the body. This is prescribed to lower the low density lipoprotein (LDL) cholesterol in the body and thus reduce mortality in high-risk patients. Demand for statins is long driven by increasing healthcare awareness among the common masses.
Though cholesterol level is easy to maintain provided one follows a healthy diet, sedentary lifestyle has been a major challenge over the past several years.
Over the past few years, the statins market has proved to be a lucrative and profitable market, especially for players that are focused on it. Consumption of statins is quite high among the geriatric population.
Rise in the prevalence of cholesterol owing to changing lifestyles has led to increased demand for statins worldwide. There has been a significant rise in patients with obesity, cardiovascular diseases, and diabetes, which, in turn, is expected to drive the demand for statins worldwide.
Furthermore, an increase in healthcare expenditure in emerging regions along with technological advancement, modern healthcare amenities, and various cholesterol-related healthcare campaign is expected to boost overall demand for stains worldwide.
Though the market is poised to grow at a significant rate, increasing preference for alternative medicines in emerging regions is proving a major challenge for the overall growth of the stains market.
Attribute | Details |
---|---|
Forecast Period |
2022-2032 |
Historical Data Available for |
2012-2021 |
Market Analysis |
USD Million for Value |
Key Countries Covered |
|
Key Market Segments Covered |
|
Key Companies Profiled |
|
Report Coverage |
|
Customization & Pricing |
Available upon Request |
By Drug Class:
By Therapeutic Treatment:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global statins market is projected to reach US$ 22 Bn by 2032.
The global market for statins is estimated to expand at a CAGR of 3.5% during the forecast period.
Increasing incidence of high cholesterol & obesity is expected to drive the global statins market.
North America enjoys the biggest share in the global statins market, with the U.S. leading the way.